Muthusamy Shanmugam Sells 7,414 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 7,414 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the completion of the sale, the chief operating officer now owns 825,206 shares of the company’s stock, valued at $54,735,913.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total transaction of $622,608.00.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total transaction of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total transaction of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $55.95, for a total transaction of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $55.30, for a total transaction of $541,055.20.

ANI Pharmaceuticals Stock Down 1.4 %

ANIP opened at $64.58 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81. The company’s 50-day moving average is $64.77 and its 200 day moving average is $58.57. ANI Pharmaceuticals, Inc. has a fifty-two week low of $36.99 and a fifty-two week high of $70.81. The firm has a market capitalization of $1.36 billion, a P/E ratio of 76.88 and a beta of 0.79.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The company had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. Research analysts expect that ANI Pharmaceuticals, Inc. will post 3.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 price objective on the stock. Finally, HC Wainwright raised their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $80.00.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Global Alpha Capital Management Ltd. raised its position in ANI Pharmaceuticals by 15.9% in the third quarter. Global Alpha Capital Management Ltd. now owns 525,528 shares of the specialty pharmaceutical company’s stock worth $30,512,000 after acquiring an additional 72,200 shares during the period. ClariVest Asset Management LLC raised its position in ANI Pharmaceuticals by 36.7% in the third quarter. ClariVest Asset Management LLC now owns 51,338 shares of the specialty pharmaceutical company’s stock worth $2,980,000 after acquiring an additional 13,792 shares during the period. Charles Schwab Investment Management Inc. raised its position in ANI Pharmaceuticals by 287.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 146,989 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after acquiring an additional 109,015 shares during the period. Skandinaviska Enskilda Banken AB publ bought a new stake in ANI Pharmaceuticals in the third quarter worth about $685,000. Finally, EAM Investors LLC bought a new stake in ANI Pharmaceuticals in the third quarter worth about $1,489,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.